Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects

Immunogenicity Data from Phase 1/2a Trial Highlighted at 39th Annual International Herpesvirus Workshop July 22, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above …

Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy

July 21, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2). “Consistent with our long-standing development plans, this Phase 2 trial will compare the best dose of GEN-003 from our Phase 1/2a trial …

Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003

Full Data in Oral Presentation at Major Infectious Disease Medical Meeting in October 2014 June 1, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company’s immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the …

Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation

Phase 2 trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, an important clinical surrogate Trial shows booster shot demonstrates sustainable, long-term effect June 23, 2014 Agenus Inc., an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced promising Phase 2 results for …

NanoBio’s Intranasal Vaccine Demonstrates Robust Protection Against Herpes Simplex-2 Infection

April 28, 2014 NanoBio Corporation today announced that the company will present new data at the National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (NFID ACVR), demonstrating the benefits of its nanoemulsion (NE) adjuvant in the development of an intranasal herpes simplex virus-2 (HSV-2) vaccine. HSV-2 is a leading cause of genital herpes, a sexually transmitted disease affecting …

Agenus herpes vaccine in phase II success

Agenus' experimental genital herpes vaccine has shown success in a phase II trial, the company has announced. The recombinant therapeutic vaccine, HerpV, reduced viral shedding and viral load by 15% and 34% respectively, and Anna Wald, the study's lead Principal Investigator said that "these data are exciting as we are finally seeing that we can direct the immune system to …

Published data supports innovative HSV-2 therapeutic vaccine GEN-003

Genocea Biosciences have announced the publication of preclinical trial results for their investigational therapeutic HSV-2 vaccine. The results, published in Journal of Virology, show that vaccination with GEN-003 and Isconova AB's Matrix-M adjuvant was capable of inducing antigen- and virus-specific immune responses. The vaccine improved outcomes in preclinical models of HSV-2 disease. GEN-003 showed a significant impact on viral shedding …